Poland’s Holi pockets €3M to scale its digital clinic tackling obesity across Europe

Warsaw-based Holi has completed a new funding round to grow its operations and expand its digital health services in Europe.

Warsaw-based Holi, a Polish healthtech startup developing a digital obesity clinic, has raised €3M in a seed funding round.

The investment was led by 4growth VC with participation from YZR Capital, Heartfelt Capital, and several business angels.

The company plans to use the proceeds to expand its presence in European markets and continue building its data-based care platform for obesity management.

Krzysztof Bachta, Managing Partner at 4growth VC, says, “Obesity remains one of the most underserved health needs globally. Holi has built a truly efficient care model – virtual, scalable and designed with a genuine value-for-money mindset. It delivers clinically proven outcomes at a price point that makes sense for both patients and the business. This combination of medical impact and smart product design is exactly what convinced us to invest.”

A digital platform for obesity treatment and care

According to data from the World Health Organisation, more than 800 million people live with obesity, and nearly two billion are overweight. The condition contributes to more than 200 health issues and increases demand on healthcare systems worldwide. This is where Holi looks to make a difference.

Founded in 2023, Holi is a digital obesity clinic that combines medical care with technology to support long-term health outcomes. 

Its platform connects patients with doctors, psychodietitians, psychologists, and physiotherapists, offering treatment that integrates lifestyle change with pharmacotherapy. Holi’s platform also provides access to GLP-1-based medications, including Ozempic and Wegovy, as part of coordinated treatment plans.

Through a mobile app and online platform, patients receive tailored care plans and ongoing support.

Paweł Seweryn, founder and CEO, says, “Obesity treatment requires continuity and the integration of multiple medical competencies. Our goal is to deliver a comprehensive solution that leads to real, long-term change in metabolic health.”

Currently operating through a subscription model, Holi focuses on addressing the underlying causes of obesity while helping patients improve metabolic health.

Capital utilisation

Holi will use the funds to scale its medical infrastructure and advance its technology platform. The company plans to integrate diagnostic tools, introduce GLP-1 tracking, automate care processes, and develop new engagement features to support patient participation over time.

Holi’s model combines pharmacotherapy with data-based care management and behavioural support. According to company data, patients using the platform record an average 17 per cent reduction in body weight after 12 months, about 1.5 times more than those using GLP-1 medication alone.

By aligning dose adjustment with behavioural guidance, Holi enables patients to lower medication costs by up to 50 per cent. The company aims to make long-term obesity treatment more affordable and effective through this combined approach.

Jan Kundziołka, co-founder of Holi, responsible for product and technology, says, “The next generation of obesity treatment will be hybrid – data and AI for precision, experts for impact. Our platform continuously analyses patient data to adjust therapy in real time, while doctors and specialists step in exactly when human intervention matters most. That’s how we deliver better outcomes with smarter use of medication.”

Paweł Seweryn adds, “The funding will enable us to scale our model internationally – starting with the Southern and Eastern Europe markets, which are highly receptive to private healthcare and telemedicine – while further developing our technology stack.”

“Since our initial investment, Holi has shown remarkable progress – both in clinical outcomes and operational execution. The company is scaling fast while maintaining strong medical standards, which is rare in this market. That’s exactly why we decided to significantly increase our backing in this round,” mentions Markus Feuerecker, co-founder and Managing Partner at YZR Capital.